Abstract
There is increasing evidence that antimicrobial peptides (AMPs) are differentially regulated in cancers such as oral squamous cell carcinomas (OSCC). Data showing that AMPs influence the growth of tumor cells, exhibit direct cytotoxic activity towards cancer cells, function as a tumor suppressor gene or activate the adaptive immunity suggest that a dysregulation of AMPs may be associated with the development of cancer. There is no question that, with increasing resistance against conventional chemotherapy, novel anticancer agents are needed. It is interesting to speculate that natural AMP or synthetic derivatives can be used to develop novel strategies to fight cancer diseases and may represent a novel family of anticancer agents. However, future research is needed to employ the role of AMPs in cancer and to investigate their role as potential anticancer drugs.
Keywords: Antimicrobial peptide, defensin, cathelicidin, histatin, adrenomedullin, oral cancer, immunotherapy, anticancer effect
Current Pharmaceutical Design
Title: Antimicrobial Peptides in Oral Cancer
Volume: 13 Issue: 30
Author(s): Jens E. Meyer and Jurgen Harder
Affiliation:
Keywords: Antimicrobial peptide, defensin, cathelicidin, histatin, adrenomedullin, oral cancer, immunotherapy, anticancer effect
Abstract: There is increasing evidence that antimicrobial peptides (AMPs) are differentially regulated in cancers such as oral squamous cell carcinomas (OSCC). Data showing that AMPs influence the growth of tumor cells, exhibit direct cytotoxic activity towards cancer cells, function as a tumor suppressor gene or activate the adaptive immunity suggest that a dysregulation of AMPs may be associated with the development of cancer. There is no question that, with increasing resistance against conventional chemotherapy, novel anticancer agents are needed. It is interesting to speculate that natural AMP or synthetic derivatives can be used to develop novel strategies to fight cancer diseases and may represent a novel family of anticancer agents. However, future research is needed to employ the role of AMPs in cancer and to investigate their role as potential anticancer drugs.
Export Options
About this article
Cite this article as:
Meyer E. Jens and Harder Jurgen, Antimicrobial Peptides in Oral Cancer, Current Pharmaceutical Design 2007; 13 (30) . https://dx.doi.org/10.2174/138161207782110372
DOI https://dx.doi.org/10.2174/138161207782110372 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Topical Ingenol Mebutate: A New Treatment Modality for Multiple Actinic Keratoses and Field Cancerization
Anti-Cancer Agents in Medicinal Chemistry Solid Lipid Nanoparticles Containing Nimesulide: Preparation, Characterization and Cytotoxicity Studies
Current Nanoscience Anticancer Properties of Essential Oils: An Overview
Current Cancer Drug Targets Sunlight Vitamin D and Skin Cancer
Anti-Cancer Agents in Medicinal Chemistry Reversal of ABC Drug Transporter-Mediated Multidrug Resistance in Cancer Cells: Evaluation of Current Strategies
Current Molecular Pharmacology Molecular Imaging Aided Improvement in Drug Discovery and Development
Current Biotechnology Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches
Current Medicinal Chemistry The p35 Family of Apoptosis Inhibitors
Current Genomics A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma
Current Cancer Drug Targets Azole Antimycotics - A Highway to New Drugs or a Dead End?
Current Medicinal Chemistry Patented Biomarkers of Peripheral Blood for the Early Detection of Cancer
Recent Patents on Biomarkers The Molecular Mechanisms of TRAIL Resistance in Cancer Cells: Help in Designing New Drugs
Current Pharmaceutical Design Targeted Therapies in Lung Cancer
Current Pharmaceutical Design Melanoma
Current Cancer Therapy Reviews Defensins: Key Molecules in Ocular Surface Protection
Current Immunology Reviews (Discontinued) Lipoxygenase Inhibitors for Cancer Prevention: Promises and Risks
Current Pharmaceutical Design Nitrosative Stress as a Mediator of Apoptosis: Implications for Cancer Therapy
Current Pharmaceutical Design Thrombospondin and Apoptosis: Molecular Mechanisms and Use for Design of Complementation Treatments
Current Drug Targets Intracellular Delivery of Potential Therapeutic Genes: Prospects in Cancer Gene Therapy
Current Gene Therapy Phytoconstituents of <i>Lantana camara</i> L.: Rekindling Hope in the Cancer Treatment
Current Bioactive Compounds